Alector (NASDAQ:ALEC) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen upgraded Alector (NASDAQ:ALEC) from a "sell" to a "hold" rating, contributing to a mixed analyst sentiment with a consensus "Hold" rating and an average price target of $3.25. The article highlights recent insider stock sales totaling around $220,064 and details the company's financial metrics and institutional ownership. Alector, a clinical-stage biotechnology company, focuses on developing immuno-neurology therapies for neurodegenerative disorders like Alzheimer's and frontotemporal dementia.
Alector, Inc. (NASDAQ:ALEC) Receives Average Recommendation of "Hold" from Brokerages
Alector, Inc. (NASDAQ:ALEC) has received an average "Hold" recommendation from eight brokerage firms, with a 12-month average price target of $3.25. Insiders have recently sold approximately 196,104 shares, including CEO Arnon Rosenthal, though institutional ownership remains high at 85.83%. The company, a clinical-stage biotechnology firm focused on neurodegenerative disorders, currently trades around $1.98 with a market capitalization of $216 million.
ALEC: Sector Tailwinds And Deal Optionality Will Shape Measured Future Upside
Analysts have slightly increased their consensus price target for Alector (ALEC) from US$0.75 to US$0.90, attributing it to potential tailwinds for U.S. small and mid-cap biotech firms as larger pharmaceutical companies face a patent cliff. While maintaining an "Underweight" rating, the updated outlook suggests a balance between acknowledging broader sector opportunities and lingering concerns about Alector's specific execution and fundamentals. Recent news includes Alector's removal from the NASDAQ Biotechnology Index and the appointment of Neil Berkley as CFO, effective December 10, 2025.
Legal Scrutiny Adds to Alector’s Clinical Setback Challenges
Alector Inc. is facing significant challenges, including a legal investigation by Levi & Korsinsky, following the failure of its INFRONT-3 Phase 3 clinical trial for latozinemab. The company is restructuring its executive team and shifting its strategic focus to nivisnebart, a drug candidate for Alzheimer's disease, with an interim analysis expected in the first half of 2026. Vanguard Group maintains a substantial stake in Alector, indicating continued investor interest despite the setbacks.
INVESTOR ALERT: Levi & Korsinsky is Investigating Alec Stock After its Phase 3 INFRONT-3 Clinical Trial Misses Co-Primary Endpoint
Levi & Korsinsky, LLP is investigating Alector, Inc. (NASDAQ: ALEC) following the announcement that its Phase 3 INFRONT-3 trial for latozinemab failed to meet its clinical co-primary endpoint for slowing progression in frontotemporal dementia. The trial met its biomarker response endpoint but missed the clinical response endpoint, leading analysts to downgrade the stock. The law firm is inviting investors with concerns to contact them for more information regarding Alector's operational performance.
There's No Escaping Alector, Inc.'s (NASDAQ:ALEC) Muted Revenues Despite A 32% Share Price Rise
Alector, Inc.'s stock has seen a 32% rise recently, but its muted revenue growth and a low price-to-sales (P/S) ratio of 3x suggest underlying issues. Analysts forecast a 50% annual revenue contraction over the next three years, contrasting sharply with the broader biotech industry's expected 126% growth. This weak outlook justifies Alector's low P/S ratio and could hinder long-term share price stability.
Levi & Korsinsky Announces an Investigation on Behalf of Alector, Inc. (ALEC) Shareholders Who May Have Been Affected by Fraud
Levi & Korsinsky has initiated an investigation into Alector, Inc. (ALEC) concerning potential violations of federal securities laws. This follows Alector's announcement on October 22, 2025, that its Phase 2 clinical trial for latozinemab in frontotemporal dementia did not show a clinical benefit, causing ALEC's stock to drop over 52%. The firm is inviting affected shareholders to seek additional information regarding a possible class-action lawsuit.
Alector, Inc. (NASDAQ:ALEC) Given Average Rating of "Reduce" by Analysts
Nine analysts have given Alector, Inc. (NASDAQ:ALEC) an average rating of "Reduce," with a 12-month average target price of $3.25. The company currently trades around $1.52, has a market cap of $165.9 million, and reported an EPS of ($0.34) for the last quarter. Significant insider selling, including by the CEO, occurred in December, and institutional investors hold approximately 85.8% of the stock.
Investors who lost money on Alector, Inc. should contact Levi & Korsinsky about an ongoing investigation - ALEC
Levi & Korsinsky has initiated an investigation into Alector, Inc. (NASDAQ:ALEC) following a significant drop in its stock price. This investigation concerns potential violations of federal securities laws after the company announced that its Phase 2 clinical trial for latozinemab in treating frontotemporal dementia did not show clinical benefit. Investors who suffered losses are encouraged to contact Levi & Korsinsky for more information.
Alector, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - ALEC
Levi & Korsinsky has launched an investigation into Alector, Inc. (NASDAQ: ALEC) for potential federal securities law violations following a significant stock drop. This probe comes after Alector announced that its Phase 2 INFRONT-3 clinical trial for latozinemab (AL001) in frontotemporal dementia patients did not show a clinical benefit, causing its stock to fall over 52%. Investors are encouraged to contact the firm for more information.
Shareholder Rights Advocates at Levi & Korsinsky Investigate Alector, Inc. (ALEC) Regarding Possible Securities Fraud Violations
Levi & Korsinsky LLP has launched an investigation into Alector, Inc. (ALEC) following a significant stock price drop. This investigation concerns possible violations of federal securities laws after Alector announced that its Phase 2 clinical trial for latozinemab in FTD-GRN patients did not demonstrate a clinical benefit. The news led to ALEC's stock price falling over 52%.
Shareholder Rights Advocates at Levi & Korsinsky Investigate Alector, Inc. (ALEC) Regarding Possible Securities Fraud Violations
Levi & Korsinsky has launched an investigation into Alector, Inc. (ALEC) concerning potential federal securities law violations. This comes after Alector announced on October 22, 2025, that its Phase 2 clinical trial for latozinemab (AL001) in patients with FTD-GRN did not demonstrate clinical benefit, leading to a significant 52% drop in ALEC's stock price. The firm is inviting investors affected by this news to contact them for additional information regarding a possible securities fraud lawsuit.
Shareholder Rights Advocates at Levi & Korsinsky Investigate Alector, Inc. (ALEC) Regarding Possible Securities Fraud Violations
Levi & Korsinsky has launched an investigation into Alector, Inc. (ALEC) concerning potential federal securities law violations. This investigation follows a significant 52% drop in ALEC's stock price after the company announced on October 22, 2025, that its Phase 2 INFRONT-3 clinical trial for latozinemab (AL001) failed to demonstrate a clinical benefit in slowing the progression of frontotemporal dementia due to a progranulin gene mutation (FTD-GRN). The firm encourages aggrieved shareholders to seek additional information regarding the lawsuit.
Shareholder Rights Advocates at Levi & Korsinsky Investigate Alector, Inc. (ALEC) Regarding Possible Securities Fraud Violations
Levi & Korsinsky has launched an investigation into Alector, Inc. (ALEC) for potential federal securities law violations. This comes after Alector's announcement on October 22, 2025, that its latozinemab treatment (AL001) in the Phase 2 INFRONT-3 clinical trial did not show clinical benefit for slowing FTD-GRN progression, causing ALEC's stock to drop over 52%. The firm is inviting affected investors to seek additional information regarding the possible securities fraud.
Alector, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - ALEC
Levi & Korsinsky has initiated an investigation into Alector, Inc. (NASDAQ: ALEC) for potential federal securities law violations. This comes after Alector announced on October 22, 2025, that its latozinemab drug did not show clinical benefit in slowing frontotemporal dementia progression, causing the stock price to drop over 52%. Investors are encouraged to contact Levi & Korsinsky for more information regarding potential securities fraud allegations.
Shareholders that lost money on Alector, Inc.(ALEC) should contact Levi & Korsinsky about Securities Fraud Investigation - ALEC
Levi & Korsinsky has initiated an investigation into Alector, Inc. (NASDAQ: ALEC) following a significant drop in its stock price. This investigation comes after Alector announced that its Phase 2 clinical trial for latozinemab (AL001) in frontotemporal dementia did not show clinical benefit, causing the stock to fall over 52%. Shareholders who lost money are encouraged to contact Levi & Korsinsky for more information regarding potential federal securities law violations.
Shareholders that lost money on Alector, Inc.(ALEC) should contact Levi & Korsinsky about Securities Fraud Investigation - ALEC
Levi & Korsinsky has initiated an investigation into Alector, Inc. (ALEC) regarding potential violations of federal securities laws. This follows Alector's announcement of negative results from its Phase 2 clinical trial for latozinemab, which caused ALEC's stock price to drop significantly by over 52%. The firm is inviting affected shareholders to contact them for more information on the securities fraud investigation.
Investigation Alert: Alector, Inc. (ALEC) Under Scrutiny - Contact Levi & Korsinsky For Details
Levi & Korsinsky has initiated an investigation into Alector, Inc. (NASDAQ: ALEC) following a significant stock price drop. This comes after the announcement of disappointing results from the Phase 2 INFRONT-3 clinical trial of latozinemab, which failed to show a clinical benefit in slowing FTD-GRN progression. The firm is inviting investors who suffered losses to contact them regarding potential violations of federal securities laws.
Alector Stock Down After Latozinemab Failure, Eyes On Phase 2 Catalyst (ALEC)
Alector, Inc. (ALEC) has experienced a significant stock drop following the Phase 3 failure of its drug Latozinemab. The company is now trading at a deep discount, with investor focus shifting to Nivisnebart, an Alzheimer's treatment, which is ALEC's next major catalyst with interim Phase 2 data expected in early 2026. While both Nivisnebart and Latozinemab share a core mechanism, raising some investor caution, the current valuation reflects pipeline uncertainty and cash strength, leading to a "hold" recommendation until positive Nivisnebart data emerges.
Alector (ALEC) Appoints Neil Berkley as CFO
Alector (ALEC) has appointed Neil Berkley as Chief Financial Officer, effective December 10, 2025, while he will also retain his responsibilities as Chief Business Officer. The biotechnology company, which focuses on neurodegenerative therapies, faces significant financial challenges including negative margins and declining revenue growth. Despite a stable liquidity position, an Altman Z-Score of -3.61 indicates potential bankruptcy risk, and recent insider activity shows substantial selling with no buying.
Alector, Inc. Appoints Neil Berkley as Chief Financial Officer
Alector, Inc. has appointed Neil Berkley as Chief Financial Officer, effective December 10, 2025. Berkley, who served as Chief Business Officer and Interim CFO, will retain his CBO role. CEO Arnon Rosenthal praised Berkley's leadership and extensive biotech experience as crucial for Alector's strategic advancements in neurodegeneration therapies.
Alector, Inc. Appoints Neil Berkley as Chief Financial Officer
Alector, Inc., a biotechnology company, has appointed Neil Berkley as Chief Financial Officer, effective December 10, 2025. Berkley will also retain his role as Chief Business Officer, bringing over two decades of experience in biotechnology to navigate the company through a critical development period. The appointment is expected to strengthen Alector's strategic and financial leadership as it advances therapies for neurodegenerative diseases.
Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer
Alector, Inc., a clinical-stage biotechnology company, has appointed Neil Berkley as its Chief Financial Officer, effective December 10, 2025. Mr. Berkley will also continue to serve as Chief Business Officer, a role he has held since March 2024 (and interim CFO since June 2025). The company highlighted his exceptional leadership, strategic insight, and deep understanding of their science and business as key qualifications for his expanded role.
Alector (NASDAQ: ALEC) appoints Neil Berkley as CFO while retaining chief business officer role
Alector (NASDAQ: ALEC) has appointed Neil Berkley as Chief Financial Officer, effective December 10, 2025, while he also continues in his role as Chief Business Officer. Berkley brings over two decades of experience in corporate strategy, finance, and business development to the position, having served as Interim CFO since June 2025. This appointment consolidates leadership as Alector navigates a strategic refocusing period following a recent failed Phase 3 trial and workforce reduction.
Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer
Alector, Inc. has appointed Neil Berkley as its Chief Financial Officer, effective December 10, 2025. Mr. Berkley previously served as the company's Chief Business Officer since March 2024 and CBO and Interim CFO since June 2025, and will continue in the CBO role. This appointment recognizes his leadership, strategic insight, and deep understanding of the company's operations and financial aspects as Alector advances its neurodegeneration therapies.
Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company, has appointed Neil Berkley as its Chief Financial Officer, effective December 10, 2025. Berkley will also continue his role as Chief Business Officer, a position he has held since March 2024, bringing over two decades of experience in biotech corporate strategy, finance, and business development to his expanded role. This appointment is expected to support Alector's strategic priorities and the advancement of its pipeline in neurodegenerative diseases.
Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer
Alector, Inc. has announced the appointment of Neil Berkley as its Chief Financial Officer, effective December 10, 2025. Mr. Berkley, who has been with Alector since March 2024 and previously served as Chief Business Officer and Interim CFO, will continue in the Chief Business Officer role. This appointment recognizes his leadership, strategic insight, and deep understanding of the company's science and business drivers.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Alector, Inc. (ALEC) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating Alector, Inc. (ALEC) following a significant stock price drop. This comes after Alector announced that its Phase 3 clinical trial for latozinemab (AL001) in frontotemporal dementia did not meet its primary or secondary endpoints. The firm is encouraging investors who purchased Alector securities to connect and assist with the investigation.
Alector principal accounting officer Wong-Sarad sells $5,751 in stock
Grace Wong-Sarad, Principal Accounting Officer at Alector, Inc. (NASDAQ:ALEC), sold 4,753 shares of common stock for $5,751 on December 5, 2025, under a pre-arranged trading plan. This sale occurred while Alector's stock has seen significant declines and after recent clinical trial failures for its drug latozinemab. Despite the stock's downturn and analyst downgrades, InvestingPro suggests Alector appears undervalued, holding more cash than debt, though it is burning through cash reserves.
Alector principal accounting officer Wong-Sarad sells $5,751 in stock By Investing.com
Grace Wong-Sarad, Principal Accounting Officer at Alector, Inc. (NASDAQ:ALEC), sold 4,753 shares of common stock for $5,751 on December 5, 2025. This sale occurred as Alector's stock has declined significantly, and the company is also facing challenges from the discontinuation of its INFRONT-3 clinical trial for latozinemab, leading to analyst downgrades.
Alector, Inc. (NASDAQ:ALEC) Receives Average Rating of "Reduce" from Brokerages
Alector, Inc. (NASDAQ:ALEC) has received an average rating of "Reduce" from ten brokerage firms, with a consensus 12-month price target of $3.40. Key insiders, including CEO Arnon Rosenthal and CFO Neil Lindsay Berkley, recently sold shares, reducing insider ownership to 9.70%. Despite insider selling, institutional investors and hedge funds own 85.83% of the stock, with notable increases in stakes by firms like Millennium Management.
Sara Kenkare-Mitra Sells 41,687 Shares of Alector (NASDAQ:ALEC) Stock
Insider Sara Kenkare-Mitra sold 41,687 shares of Alector (NASDAQ:ALEC) stock at an average price of $1.12 on December 3rd, reducing her stake by 7.67%. The transaction totaled approximately $46,689.44. Alector, trading near $1.14 with a market cap of $124.43M, has a consensus analyst rating of "Reduce" and a $3.00 price target.
Neil Lindsay Berkley Sells 37,261 Shares of Alector (NASDAQ:ALEC) Stock
Alector CFO Neil Lindsay Berkley recently sold 37,261 shares of the company's stock, reducing his stake by 9.05%. The transaction, valued at approximately $41,732, occurred while Alector stock is trading near $1.14 with a market capitalization of $124.4 million. Despite an EPS beat, the company remains unprofitable, and analysts generally have a "Reduce" rating with a $3.00 price target.
Alector to Participate in the Bank of America CNS Therapeutics Conference
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company, announced its management will participate in a fireside chat at the Bank of America CNS Therapeutics Conference on Monday, December 8, 2025, at 2:25 pm ET. A webcast of the event will be available on the company's investor relations website, with a replay accessible for 90 days following the conference. Alector focuses on developing therapies for neurodegenerative diseases and is advancing a portfolio of programs, including the Alector Brain Carrier (ABC) platform.
Alector to Participate in the Bank of America CNS Therapeutics Conference
Alector, Inc. (Nasdaq: ALEC) announced that its management will participate in a fireside chat at the Bank of America CNS Therapeutics Conference on Monday, December 8, 2025, at 2:25 pm ET. A webcast of the event will be available on the company's investor relations website for 90 days. Alector is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases.
Alector, Inc. (ALEC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Alector, Inc. (ALEC) following a nearly 50% stock price drop. The investigation comes after Alector announced that its drug candidate, latozinemab (AL001), failed to meet its primary and secondary endpoints in the Phase 3 INFRONT-3 clinical trial for frontotemporal dementia. Investors who purchased Alector securities are encouraged to contact the firm.
ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm is investigating claims on behalf of investors of Alector, Inc. (NASDAQ: ALEC) following a significant drop in stock price. This investigation stems from the company's announcement that its drug candidate, latozinemab (AL001), failed to meet its primary endpoint in a Phase 3 clinical trial for frontotemporal dementia. Shareholders who experienced losses are encouraged to contact the firm for a free consultation.
ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm is investigating Alector, Inc. (NASDAQ: ALEC) on behalf of investors for potential securities law violations. This investigation follows a significant stock drop after Alector announced that its drug candidate, latozinemab, failed to meet the primary endpoint in a Phase 3 clinical trial for frontotemporal dementia. Shareholders who experienced losses are encouraged to contact the firm.
Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update
Alector announced that its Phase 3 INFRONT-3 clinical trial for latozinemab in individuals with frontotemporal dementia due to a GRN mutation (FTD-GRN) did not meet its clinical co-primary endpoint. While the drug showed a statistically significant effect on plasma progranulin concentrations, no clinical benefit was observed, leading to the discontinuation of further studies for latozinemab. In response, Alector is reducing its workforce by 49% and focusing on its pipeline programs, including nivisnebart for Alzheimer’s disease and other programs utilizing its Alector Brain Carrier (ABC) technology.
Alector Reports Third Quarter 2025 Financial Results and Provides Business Update
Alector, Inc. reported its third-quarter 2025 financial results, highlighting a strong cash position of $291.1 million, expected to fund operations through 2027. The company is advancing several Alector Brain Carrier (ABC)-enabled programs, including AL137 for Alzheimer's and AL050 for Parkinson's, towards IND-enabling studies, with IND submissions targeted for 2026 and 2027. Additionally, an independent interim analysis for the PROGRESS-AD Phase 2 trial of nivisnebart (AL101) in early Alzheimer’s disease is planned for the first half of 2026.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Alector, Inc. (ALEC) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has announced an investigation into Alector, Inc. (ALEC) following a significant drop in its stock price. This investigation stems from Alector's recent announcement that its Phase 3 clinical trial for latozinemab (AL001) in frontotemporal dementia did not meet its primary endpoint. The firm encourages investors who purchased Alector securities to learn more about the investigation.
Did Alector, Inc. (ALEC) Mislead Investors? Levi & Korsinsky Investigates
Levi & Korsinsky has launched an investigation into Alector, Inc. (NASDAQ:ALEC) regarding potential violations of federal securities laws. This follows Alector's announcement of its Phase 2 INFRONT-3 clinical trial results, which indicated latozinemab did not demonstrate a clinical benefit for slowing FTD-GRN progression, causing ALEC's stock price to drop over 52%. The firm is inviting investors to obtain additional information about the investigation.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alector, Inc. - ALEC
Pomerantz LLP is investigating Alector, Inc. (ALEC) on behalf of investors regarding potential securities fraud or unlawful business practices. This investigation follows Alector's announcement that its Phase 3 INFRONT-3 clinical trial for latozinemab did not meet its primary endpoint, causing a significant drop in the company's stock price. The firm encourages affected investors to contact them to learn more about joining a potential class action.
Alector, Inc. (ALEC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Alector, Inc. (ALEC) shareholders following a significant stock price drop. The investigation stems from Alector's announcement that its Phase 3 INFRONT-3 clinical trial for latozinemab did not meet its primary endpoint, causing the stock to fall by 49.84%. Shareholders are encouraged to contact the firm to learn more about the investigation into Alector.
Alector (ALEC): Assessing Valuation After Phase 3 Trial Failure and Major Business Overhaul
Alector (ALEC) experienced a significant stock plunge after its experimental therapy, latozinemab, failed to meet its primary efficacy goal in a Phase 3 trial for frontotemporal dementia. This failure led to the discontinuation of follow-up studies and a major reorganization of the company. Despite steep losses and a negative one-year return, Simply Wall St's analysis suggests Alector may be undervalued, citing its proprietary expertise and platform for CNS drug development and future potential partnerships.
Bay Area biotech company Alector cuts dozens of jobs after drug reportedly flops
Bay Area biopharmaceutical company Alector, Inc. is laying off 75 employees at its South San Francisco headquarters following the reported failure of a phase III trial for its dementia drug. This reduction in workforce amounts to about a third of the company's total headcount. The unsuccessful trial, which found no clinical benefit for patients with frontotemporal dementia, caused Alector's stock to fall by 51%.
What Alector’s Phase III miss may say about FTD biology: Clinical Report
Alector Inc. (NASDAQ:ALEC) experienced a 50% stock drop after its SORT1-targeting antibody, latozinemab, failed to slow disease progression in frontotemporal dementia patients with GRN mutations (FTD-GRN) during the INFRONT-3 Phase III trial. This clinical report analyzes the implications of Alector's Phase III miss for understanding FTD biology. The news led to significant stock movements among smaller biotechs focused on neurological disorders.
Alector dementia drug, partnered with GSK, fails in key study
Alector's experimental dementia drug, AL001 (latozinemab), developed in partnership with GSK, failed to meet its primary endpoint in a Phase 3 clinical trial, causing Alector's stock to plummet by 51%. The negative results have led Alector to cut nearly half its workforce and prompted its research and development chief to resign. Despite this setback, Alector plans to continue advancing its pipeline, including a Phase 2 trial for another drug, nivisnebart, with interim results expected next year.
Cowen downgrades Alector stock to Hold after Phase 3 trial failure
Cowen downgraded Alector Inc. (NASDAQ:ALEC) from Buy to Hold after its Phase 3 INFRONT-3 trial for latozinemab failed to meet its primary endpoint, effectively ending the drug's development. Despite a recent stock surge and positive earnings, the clinical trial's failure and high cash burn led to the downgrade. Alector will now focus on other pipeline drugs and has implemented a 49% headcount reduction.
Alector halves staff after GSK-partnered antibody flops phase 3 dementia trial
Alector Therapeutics is undergoing a significant restructuring, including a 49% staff reduction and the resignation of its head of R&D, after its GSK-partnered antibody, latozinemab, failed to slow disease progression in a phase 3 trial for frontotemporal dementia (FTD). The company is now shifting its focus to another GSK collaboration, a phase 2 trial for Alzheimer's disease using nivisnebart, while continuing development of its wholly-owned preclinical pipeline. This follows a previous restructure in 2024 after another Alzheimer's antibody failed a phase 2 trial.
